Timothy Hughes, MD, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, shares some insights into a study comparing the use of nilotinib versus a nilotinib plus imatinib switch approach for the frontline treatment of chronic myeloid leukemia (CML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.